Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: Adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides | Zendy

Temperton Nigel J. | Zendy; Quenelle Debra C. | Zendy; Lawson Keirissa M. | Zendy; Zuckerman Jane N. | Zendy; Kern Earl R. | Zendy; Griffiths Paul D. | Zendy; Emery Vincent C. | Zendy

Premium

Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: Adjuvant effects of aluminum phosphate and CpG oligodeoxynucleotides

Author(s) -

Temperton Nigel J.,

Quenelle Debra C.,

Lawson Keirissa M.,

Zuckerman Jane N.,

Kern Earl R.,

Griffiths Paul D.,

Emery Vincent C.

Publication year - 2003

Publication title -

journal of medical virology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.782

H-Index - 121

eISSN - 1096-9071

pISSN - 0146-6615

DOI - 10.1002/jmv.10357

Subject(s) - adjuvant , cpg oligodeoxynucleotide , virology , antibody , immunization , human cytomegalovirus , neutralizing antibody , cpg site , immune system , antibody titer , titer , immunology , biology , virus , biochemistry , gene expression , dna methylation , gene

A human cytomegalovirus (HCMV) glycoprotein B (gpUL55) DNA vaccine has been evaluated in BALB/c mice. Intramuscular immunization of these mice with pRc/CMV2‐gB resulted in the generation of high levels of gpUL55‐specific antibody (geometric mean titer [GMT] 1:8900) and neutralizing antibody (GMT 1:74) after 2 booster doses given 5 and 10 weeks after primary inoculation. Emulsifying the construct with the aluminum phosphate gel adjuvant Adju‐Phos before immunization enhanced gpUL55‐specific antibody responses (GMT 1:17800, P = 0.04). Co‐immunization with CpG oligodeoxynucleotides was shown to enhance levels of neutralizing antibodies generated by immunization of mice with a pRc/CMV2‐gB/Adju‐Phos emulsion ( P = 0.04). The results provide a rationale for evaluating combinations of other HCMV proteins for incorporation into a multi‐target DNA vaccine, and for the optimization of adjuvant usage, to elicit enhanced levels of neutralizing antibodies. J. Med. Virol. 70:86–90, 2003. © 2003 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research